Inhibitory and fungicidal effects of antifungal drugs against Aspergillus species in the presence of serum
- PMID: 23318807
- PMCID: PMC3623331
- DOI: 10.1128/AAC.01573-12
Inhibitory and fungicidal effects of antifungal drugs against Aspergillus species in the presence of serum
Abstract
Given the high protein binding rates of antifungal drugs and the effect of serum proteins on Aspergillus growth, we investigated the in vitro pharmacodynamics of amphotericin B, voriconazole, and three echinocandins in the presence of human serum, assessing both inhibitory and fungicidal effects. In vitro inhibitory (IC) and fungicidal (FC) concentrations against 5 isolates of Aspergillus fumigatus, Aspergillus flavus, and Aspergillus terreus were determined with a CLSI M38-A2-based microdilution method using the XTT methodology after 48 h of incubation at 35 °C with a medium supplemented with 50% human serum. In the presence of serum, the IC and FC of amphotericin B and the IC of echinocandins were increased (1.21- to 13.44-fold), whereas voriconazole IC and FC were decreased (0.22- to 0.90-fold). The amphotericin B and voriconazole FC/IC ratios did not change significantly (0.59- to 2.33-fold) in the presence of serum, indicating that the FC increase was due to the IC increase. At echinocandin concentrations above the minimum effective concentration (MEC), fungal growth was reduced by 10 to 50% in the presence of human serum, resulting in complete inhibition of growth for some isolates. Thus, the in vitro activities of amphotericin B and echinocandins were reduced, whereas that of voriconazole was enhanced, in the presence of serum. These changes could not be predicted by the percentage of protein binding, indicating that other factors and/or secondary mechanisms may account for the observed in vitro activities of antifungal drugs against Aspergillus species in the presence of serum.
Figures

Similar articles
-
Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions.Antimicrob Agents Chemother. 2013 Oct;57(10):4656-63. doi: 10.1128/AAC.00597-13. Epub 2013 Jul 15. Antimicrob Agents Chemother. 2013. PMID: 23856768 Free PMC article.
-
Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology.Antimicrob Agents Chemother. 2007 Sep;51(9):3329-37. doi: 10.1128/AAC.00345-07. Epub 2007 Jun 18. Antimicrob Agents Chemother. 2007. PMID: 17576838 Free PMC article.
-
Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.Antimicrob Agents Chemother. 2012 Jan;56(1):403-10. doi: 10.1128/AAC.00662-11. Epub 2011 Nov 7. Antimicrob Agents Chemother. 2012. PMID: 22064546 Free PMC article.
-
In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.Rev Iberoam Micol. 2003 Dec;20(4):121-36. Rev Iberoam Micol. 2003. PMID: 15456349 Review.
-
Aspergillus tubingensis Endocarditis: A Case Report and Review of the Literature.Mycopathologia. 2022 Jun;187(2-3):249-258. doi: 10.1007/s11046-022-00621-0. Epub 2022 Mar 10. Mycopathologia. 2022. PMID: 35267153 Free PMC article. Review.
Cited by
-
PK/PD modeling and simulation of the in vitro activity of the combinations of isavuconazole with echinocandins against Candida auris.CPT Pharmacometrics Syst Pharmacol. 2023 Jun;12(6):770-782. doi: 10.1002/psp4.12949. Epub 2023 Mar 13. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 36915233 Free PMC article.
-
Hydroxychavicol: A phytochemical targeting cutaneous fungal infections.Sci Rep. 2016 Nov 29;6:37867. doi: 10.1038/srep37867. Sci Rep. 2016. PMID: 27897199 Free PMC article.
-
Antifungal Susceptibility in Serum and Virulence Determinants of Candida Bloodstream Isolates from Hong Kong.Front Microbiol. 2016 Feb 26;7:216. doi: 10.3389/fmicb.2016.00216. eCollection 2016. Front Microbiol. 2016. PMID: 26955369 Free PMC article.
-
Administration of Zinc Chelators Improves Survival of Mice Infected with Aspergillus fumigatus both in Monotherapy and in Combination with Caspofungin.Antimicrob Agents Chemother. 2016 Sep 23;60(10):5631-9. doi: 10.1128/AAC.00324-16. Print 2016 Oct. Antimicrob Agents Chemother. 2016. PMID: 27401578 Free PMC article.
-
Antidermatophyte activity and PK/PD of ME1111 in a guinea pig model of tinea corporis.J Antibiot (Tokyo). 2024 Aug;77(8):533-539. doi: 10.1038/s41429-024-00738-y. Epub 2024 May 20. J Antibiot (Tokyo). 2024. PMID: 38769156
References
-
- Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, Rinaldi MG, Stevens DA, Graybill JR. 2000. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 79:250–260 - PubMed
-
- Groll AH, Walsh TJ. 2002. Antifungal chemotherapy: advances and perspectives. Swiss Med. Wkly. 132:303–311 - PubMed
-
- Johnson EM, Oakley KL, Radford SA, Moore CB, Warn P, Warnock DW, Denning DW. 2000. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J. Antimicrob. Chemother. 45:85–93 - PubMed
-
- Mosquera J, Warn PA, Morrissey J, Moore CB, Gil-Lamaignere C, Denning DW. 2001. Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo. Antimicrob. Agents Chemother. 45:1456–1462 - PMC - PubMed
-
- Walsh TJ, Petraitis V, Petraitiene R, Field-Ridley A, Sutton D, Ghannoum M, Sein T, Schaufele R, Peter J, Bacher J, Casler H, Armstrong D, Espinel-Ingroff A, Rinaldi MG, Lyman CA. 2003. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J. Infect. Dis. 188:305–319 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources